Recruiting

Testing immune therapy combined with radiation for advanced esophageal cancer

Plain-English translation of NCT06792786 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a new treatment approach for advanced esophageal cancer that combines immunotherapy (medicines that help your immune system fight cancer) with chemotherapy and radiation. The study will track special cancer markers in your blood throughout treatment to help doctors understand which patients benefit most from this combined approach and to predict how the cancer might respond.

Advanced esophageal cancer has very poor survival rates with standard treatment alone. Researchers believe that combining this medication with radiation and chemotherapy may be more effective, and by monitoring blood markers called circulating tumor DNA (ctDNA), doctors may be able to personalize treatment decisions and catch cancer progression earlier than imaging alone can detect.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced esophageal squamous cell carcinoma that cannot be surgically removed or you have chosen not to have surgery
you have not received prior chemotherapy, radiation, immunotherapy, or other cancer treatments for esophageal cancer
you are in good enough health to tolerate this treatment (ECOG performance status of 0–1)
your blood counts, liver function, and kidney function are within acceptable ranges before starting treatment

You likely don't qualify if…

you have a history of other cancers in the past 5 years (except early-stage skin cancer or cervical cancer)
your cancer is located too close to your windpipe or major blood vessels, putting you at high risk for serious bleeding
you have had recent gastrointestinal bleeding, blood clotting problems, or are currently taking blood-thinning medications
you have severe heart, lung, or nervous system disease, or active tuberculosis or pneumonia
you are allergic to paclitaxel, cisplatin, or monoclonal antibody medications

What participation looks like

You would receive induction immunochemotherapy first, followed by concurrent chemotherapy and radiation therapy. Throughout this treatment, you would have repeated blood tests to monitor circulating tumor DNA levels, which help doctors track how your cancer is responding. The study involves a small group of 30 patients at a single medical center in China, and you would need to be willing to undergo dynamic blood monitoring as part of the research.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Testing immune therapy combined with radiation for advanced esophageal cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)